Enliven Therapeutics Inc. (Nasdaq: ELVN) reported this week that as of the end of 2025, the clinical-stage precision oncology company has $462.6 million in cash and equivalents, enough runway to fund ...
Enterprises seeking to make good on the promise of agentic AI will need a platform for building, wrangling, and monitoring AI agents in purposeful workflows. In this quickly evolving space, myriad ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results